Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 77,875 shares, a decline of 22.4% from the December 15th total of 100,401 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily volume of 90,581 shares, the days-to-cover ratio is currently 0.9 days. Based on an average daily volume of 90,581 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.6% of the shares of the stock are short sold.

Genenta Science Stock Performance

Shares of NASDAQ:GNTA traded up $0.05 during midday trading on Tuesday, hitting $1.35. 71,232 shares of the stock were exchanged, compared to its average volume of 68,067. The business’s 50-day moving average price is $1.65 and its 200 day moving average price is $2.79. Genenta Science has a 12 month low of $1.26 and a 12 month high of $10.00.

Genenta Science (NASDAQ:GNTA) last issued its quarterly earnings data on Friday, October 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Genenta Science will post -0.93 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC acquired a new stake in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned approximately 0.07% of Genenta Science as of its most recent SEC filing. Institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.